Breaking News, Promotions & Moves

Amgen Names Industry Veterans to Leadership Posts

James Bradner appointed executive VP, R&D and chief scientific officer and David Reese, executive vice president and chief technology officer.

Amgen appointed James Bradner executive vice president of R&D, and chief scientific officer, and David Reese executive vice president and chief technology officer. Bradner and Reese will report to Robert Bradway, Chairman and CEO at Amgen.

Bradner will be responsible for advancing Amgen’s pipeline, which includes potential first-in-class medicines in all stages of development and across the company’s four therapeutic areas of focus: oncology, inflammation, general medicine, and rare disease, in addition to biosimilars. He will also be responsible for Amgen’s worldwide research efforts.

Reese joined Amgen in 2005 and has led the R&D organization since 2018. During his tenure, Amgen has received approvals around the world for numerous innovative medicines and biosimilars. Building on Amgen’s commitment to leveraging human data in drug discovery and development, Reese has led the development of a robust pipeline. Recently he has also been the key architect of Amgen’s artificial intelligence (AI) and advanced technology initiatives with a focus on R&D. He will now be responsible for accelerating the use of technology and AI across all facets of the organization.

“For more than 40 years, Amgen’s focus on innovation has enabled us to deliver life-changing medicines to patients suffering from serious diseases around the world,” said Bradway. “The steps we are announcing today reflect our conviction that the rapid convergence of ‘biotech’ and ‘tech’ will unlock the next frontier of innovation in biotechnology.”

Keep Up With Our Content. Subscribe To Contract Pharma Newsletters